|
Q3 FY2021
As of Sep 30, 2021
|
Q2 FY2021
As of Jun 30, 2021
|
Q1 FY2021
As of Mar 31, 2021
|
Q4 FY2020
As of Dec 31, 2020
|
Q3 FY2020
As of Sep 30, 2020
|
Q2 FY2020
As of Jun 30, 2020
|
Q1 FY2020
As of Mar 31, 2020
|
Q4 FY2019
As of Dec 31, 2019
|
Q3 FY2019
As of Sep 30, 2019
|
Q2 FY2019
As of Jun 30, 2019
|
Q1 FY2019
As of Mar 31, 2019
|
Q4 FY2018
As of Dec 31, 2018
|
Q3 FY2018
As of Sep 30, 2018
|
Q2 FY2018
As of Jun 30, 2018
|
Q1 FY2018
As of Mar 31, 2018
|
Q4 FY2017
As of Dec 31, 2017
|
Q3 FY2017
As of Sep 30, 2017
|
Q2 FY2017
As of Jun 30, 2017
|
Q1 FY2017
As of Mar 31, 2017
|
Q4 FY2016
As of Dec 31, 2016
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||||||||
| Cash and due from banks | ||||||||||||||||||||
| Federal funds sold | ||||||||||||||||||||
| Interest-bearing deposits with banks | ||||||||||||||||||||
| Total cash and cash equivalents | ||||||||||||||||||||
| Securities available for sale, at fair value | ||||||||||||||||||||
| Securities held to maturity, at amortized cost | ||||||||||||||||||||
| Nonmarketable equity securities | ||||||||||||||||||||
| Loans held for sale, at fair value | ||||||||||||||||||||
| Loans and leases, net of unearned income | ||||||||||||||||||||
| Allowance for loan and lease losses | ||||||||||||||||||||
| Net loans and leases | ||||||||||||||||||||
| Bank premises and equipment, net | ||||||||||||||||||||
| Goodwill | ||||||||||||||||||||
| Core deposit intangible | ||||||||||||||||||||
| Bank owned life insurance | ||||||||||||||||||||
| Other real estate owned | ||||||||||||||||||||
| Deferred tax assets, net | ||||||||||||||||||||
| Interest receivable and other assets | ||||||||||||||||||||
| Total assets | ||||||||||||||||||||
| LIABILITIES | ||||||||||||||||||||
| Noninterest-bearing deposits | ||||||||||||||||||||
| Interest-bearing deposits | ||||||||||||||||||||
| Total deposits | ||||||||||||||||||||
| FHLB advances | ||||||||||||||||||||
| Customer repurchase agreements and other borrowings | ||||||||||||||||||||
| Subordinated debt | ||||||||||||||||||||
| Total borrowings | ||||||||||||||||||||
| Accrued expenses and other liabilities | ||||||||||||||||||||
| Total liabilities | ||||||||||||||||||||
| STOCKHOLDERS' EQUITY | ||||||||||||||||||||
| Common stock - par value of $0.01 authorized 20,000,000 shares; issued and outstanding 18,811,876 shares at September 30, 2021 and 18,744,710 at December 31, 2020 | ||||||||||||||||||||
| Capital surplus | ||||||||||||||||||||
| Retained earnings | ||||||||||||||||||||
| Accumulated other comprehensive (loss) income | ||||||||||||||||||||
| Total stockholders' equity | ||||||||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||||||||
Loading...
